Telix Pharmaceuticals Limited (ASX:TLX)
15.87
+0.46 (2.99%)
Oct 7, 2026, 4:10 PM AEST
Telix Pharmaceuticals Revenue
Telix Pharmaceuticals had revenue of $477.35M USD in the half year ending June 30, 2026, with 99.22% growth. This brings the company's revenue in the last twelve months to $890.79M, up 167.52% year-over-year. In the year 2025, Telix Pharmaceuticals had annual revenue of $803.79M with 55.61% growth. That makes Telix Pharmaceuticals the world's #8,100 largest public company by revenue and #138 in Australia.
Revenue (ttm)
$890.79M
Revenue Growth
+167.52%
P/S Ratio
4.19
Revenue / Employee
$752.35K
Employees
1,184
Market Cap
5.39B AUD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 803.79M | 287.24M | 55.61% |
| Dec 31, 2024 | 516.55M | 183.57M | 55.13% |
| Dec 31, 2023 | 332.98M | 224.03M | 205.64% |
| Dec 31, 2022 | 108.95M | 103.42M | 1,873.24% |
| Dec 31, 2021 | 5.52M | 1.51M | 37.53% |
| Dec 31, 2020 | 4.01M | 1.57M | 64.21% |
| Dec 31, 2019 | 2.44M | 2.31M | 1,680.88% |
| Dec 31, 2018 | 137.28K | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CSL Limited | 22.83B |
| Mesoblast | 173.82M |
| Clinuvel Pharmaceuticals | 94.02M |
| BLS Pharmaceuticals | 73.91M |
| Neuren Pharmaceuticals | 69.53M |
| PYC Therapeutics | 25.99M |
| Actinogen Medical | 12.67M |
| Starpharma Holdings | 12.67M |
Telix Pharmaceuticals News
- 1 day ago - First U.S. Patient Receives Telix's Newly Approved Brain Cancer Imaging Drug - Nasdaq
- 1 day ago - Telix Pharmaceuticals’ brain cancer imaging drug applied on first U.S. patients - TheFly
- 1 day ago - First Patients Dosed with Telix's FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18) - GlobeNewsWire
- 6 days ago - Ion Beam Enters Distribution Agreement For ARTMS' QIS Technology - Nasdaq
- 6 days ago - IBA and Telix strengthen ties through agreement to distribute ARTMS's QIS® - GlobeNewsWire
- 7 days ago - Wall Street Analysts Believe Telix Pharmaceuticals Limited (TLX) Could Rally 83.42%: Here's is How to Trade - Nasdaq
- 14 days ago - Telix Pharmaceuticals Limited Research and Development Day Transcript - GuruFocus
- 15 days ago - Telix Pharmaceuticals Transcript: R&D Day 2026 - Transcripts